Granules India Ltd share price logo

Granules India Ltd Share Price

(GRANULES)

₹486.350.83%

as on 04:01PM, 28 Mar 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Granules India Ltd Performance

  • Day's Low

    Day's High

    ₹482.55
    Day's Price Range
    ₹500.45
  • 52 Week's Low

    52 Week's High

    ₹389.35
    52-Week Price Range
    ₹721
1 Month Return+ 2.86 %
3 Month Return-16.68 %
1 Year Return+ 11.05 %
Previous Close₹490.40
Open₹490.50
Volume4.64L
Upper Circuit₹539.40
Lower Circuit₹441.40
Market Cap₹11,793.68Cr

Granules India Ltd Fundamentals

P/E Ratio

24.6

PEG Ratio

7.13

Market Cap

₹11,793.68 Cr

P/B Ratio

3.35

EPS

16.72

Dividend Yield

0.35

Sector

Pharmaceuticals

ROE

15

Granules India Ltd Analyst Rating

based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts offering long term price targets for Granules India Ltd. An average target of ₹646.88

Source: S&P Global Market Intelligence

Granules India Ltd Share analysis

Granules India Ltd price forecast by 8 analysts

Upside of33.01%

High

₹700

Target

₹646.88

Low

₹580

Granules India Ltd target price ₹646.88, a slight upside of 33.01% compared to current price of ₹486.35. According to 8 analysts rating.

Source: S&P Global Market Intelligence

Key events for Granules India Ltd

  • Granules India Faces Losses Amid Tariff Concerns - 27 Mar, 2025

    Granules India Ltd experienced losses in trading on March 27, 2025, as Indian pharma stocks declined for the third consecutive session due to fears of potential tariffs on pharmaceutical imports by US President Donald Trump.
  • Granules India Restructures US Operations Amid Stock Decline - 25 Mar, 2025

    Granules India Ltd's board approved a restructuring plan to consolidate US subsidiaries, transferring assets to Granules Pharma Inc. The stock fell to an intraday low of Rs. 500.15, reflecting market concerns amid the restructuring efforts.
  • Granules Europe Subsidiary Voluntarily Dissolved - 19 Mar, 2025

    Granules India Ltd announced the voluntary dissolution of its subsidiary, Granules Europe, in Bath, UK, effective March 18, due to a strategic shift in its business model.
  • Granules India Shares Show Resilience Amid Market Weakness - 04 Mar, 2025

    Granules India shares rose 1.02% to ₹478.00 despite broader market weakness. The stock has seen a 16.55% decline over the past month but has delivered strong long-term returns, gaining 67% over two years and 176% over five years.
  • Granules India Shares Volatile Amid LIC Stake Increase - 03 Mar, 2025

    Granules India shares experienced volatility on March 3, 2025, falling 7% after a US FDA warning letter, then rising nearly 3% as LIC increased its stake to 5.02%. This reflects growing institutional confidence despite regulatory challenges.
  • Granules India Faces FDA Warning Letter Challenges - 27 Feb, 2025

    Granules India Ltd received a warning letter from the US FDA for its Gagillapur facility, potentially delaying product approvals. However, existing operations continue unaffected, and the company is confident in resolving the issues promptly.

Insights on Granules India Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 7.86% to 10.39% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 969.87 Cr → 1.14K Cr (in ₹), with an average increase of 15.2% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 97.23 Cr → 117.6 Cr (in ₹), with an average increase of 17.3% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, GRANULES stock has moved up by 6.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 79.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 70.5% return, outperforming this stock by 56.4%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 38.87% to 38.85% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 19.49% to 15.87% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 26.78% to 25.71% in Dec 2024 quarter

Granules India Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹1,149.71Cr (-)₹1,169.06Cr (↑1.68%)₹1,169.11Cr (-)₹956.52Cr (↓18.18%)₹1,133.52Cr (↑18.50%)
Net Income₹125.65Cr (-)₹129.65Cr (↑3.18%)₹134.65Cr (↑3.86%)₹97.23Cr (↓27.79%)₹117.60Cr (↑20.95%)
Net Profit Margin10.93% (-)11.09% (↑1.46%)11.52% (↑3.88%)10.16% (↓11.81%)10.37% (↑2.07%)
Value in ₹ crore
Details2021202220232024
Total Assets₹3,711.98Cr (-)₹4,398.96Cr (↑18.51%)₹4,540.94Cr (↑3.23%)₹5,039.53Cr (↑10.98%)
Total Liabilities₹1,549.36Cr (-)₹1,868.30Cr (↑20.59%)₹1,841.48Cr (↓1.44%)₹1,928.58Cr (↑4.73%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹494.79Cr (-)₹374.66Cr (↓24.28%)₹280.29Cr (↓25.19%)₹663.68Cr (↑136.78%)₹316.93Cr (↓52.25%)

Granules India Ltd Index Inclusions

Nifty 500

₹21,339.55

-0.32 (-68.4%)

NIFTY PHARMA

₹21,137.45

-0.65 (-137.7%)

S&P BSE 250 SmallCap

₹6,039.25

-0.45 (-27.45%)

BSE Healthcare

₹41,421.50

-0.12 (-48.19%)

Nifty MidSmallcap 400

₹17,677.95

-0.2 (-36.15%)

Nifty Healthcare

₹13,681.30

-0.47 (-64.15%)

BSE 500

₹33,579.22

-0.39 (-132.39%)

S&P BSE 400 MidSmallCap

₹10,772.07

-0.52 (-56.71%)

Nifty Smallcap 250

₹15,104.05

-0.05 (-7.6%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

BSE Small-Cap

₹46,638.13

-0.35 (-165.52%)

Granules India Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
38.85%
-0.05
Foreign Institutions
15.87%
-18.58
Mutual Funds
10.39%
32.21
Retail Investors
25.71%
-3.98
Others
9.18%
31.04

Granules India Ltd Key Indicators

Details20202021202220232024
Earning Per Share (₹)13.1922.1816.6421.3416.72
Details20202021202220232024
Return On Equity %19.7127.8216.4719.0715
Details20202021202220232024
Return On Assets %10.5914.89.3811.388.04
Details20202021202220232024
Book Value Per Share (₹)72.5287.75104.29117.13133.08

Granules India Ltd Valuation

Granules India Ltd in the last 5 years

  • Overview

  • Trends

Lowest (8.05x)

July 25, 2019

Today (24.60x)

March 28, 2025

Industry (53.18x)

March 28, 2025

Highest (35.36x)

August 30, 2024

LowHigh

Granules India Ltd Earnings and Dividends

  • Granules India Ltd Earnings Results

    Granules India Ltd’s net profit fell -6.41% since last year same period to ₹117.60Cr in the Q3 2024-2025. On a quarterly growth basis, Granules India Ltd has generated 20.95% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Granules India Ltd Dividends May,2024

    In the quarter ending March 2024, Granules India Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.62%.

    Read More about Dividends

Granules India Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Granules India Ltd is currently in a Bearish trading position according to technical analysis indicators.

Granules India Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹11,793.68 Cr49.33%0.63₹405 Cr₹4,506 Cr
BUY₹29,300.43 Cr221.22%0.52₹300 Cr₹1,051 Cr
BUY₹14,271.69 Cr68.11%0.57₹72 Cr₹6,702 Cr
NA₹4,800.00 Cr13.52%0.79-₹388 Cr₹75 Cr
BUY₹14,234.50 Cr42.27%0.68₹218 Cr₹1,296 Cr

About Granules India Ltd

Granules India Limited is a large-scale vertically-integrated company found in March 1991. It manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. The company has a strong presence in off-patent drugs, first-line defence products such as Paracetamol, Ibuprofen, Metformin, and Guaifenesin, as well as a global presence in over 80 countries and 250 customers. It also has a 15,000 sq. ft. research center in Pragathi Nagar, Hyderabad and has completed expansion projects in Gagillapur and Visakhapatnam. In FY 2014-15, the company crossed Rs 1200 crore in revenue, made its first acquisition, and increased its PFI capacity by 4000 tons / annum. During 2015-16 it initiated construction of 7000 TPA Metformin and 2000 TPA Guaifenesin API block, and has a total of 22 EDMF/CEP and 44 ANDA filings with US FDA. In FY 2017 the company received Establishment Inspection Report from US FDA for its Jeedimetla plant and license from the Drug Enforcement Agency for its Virginia facility. In FY 2018, it crossed Rs 1400 crore in revenue and initiated commercial production of Metaformin and Paracetamol API at its Bonthapally facility. The company also successfully received 7 ANDAs approvals from US FDA. In FY 2019, Granules India initiated buyback programme, with the Board of Directors approving a buyback of up to 12.5 million equity shares on 21 January 2020. The Company has divested its entire 50% shareholding in GranulesBiocause Pharmaceutical Co. Ltd and Granules Omnichem Private Ltd. for a consideration of Rs 111.2 crore. During the year 2021, Granules Pharmaceuticals Inc. announced a voluntary recall of 12 batches of Metformin Hydrochloride Extended Release tablets USP 750 mg, out of caution. In 2022, the Company completed the largest single manufacturing site for Multiple Unit Pellet System MUPS at its Gagillapur facility and capacity expansion for manufacturing multiple APIs at Unit V Visakhapatnam. In a span of over 30 years, Granules India has firmly established its leadership in the off-patent drugs segment, and a strong presence in first line of defense products, creating a global presence in over 80 countries, servicing over 250 customers and filing 66 EDMF/CE

Revenue: ₹1,133.52Cr as on December 2024 (Q4 24)
Net Profit: ₹117.60Cr as on December 2024 (Q4 24)
Listing date: 20 Jun, 2005
Chairperson Name: C Krishna Prasad
OrganisationGranules India Ltd
HeadquartersHyderabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Granules India Ltd

What is Granules India Ltd price today?

Granules India Ltd share price today stands at ₹486.35, Open: ₹490.5, Previous Close: ₹490.4, High: ₹500.45, Low: ₹482.55, 52 Week High: ₹721, 52 Week Low: ₹389.35.

How to Buy Granules India Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Granules India Ltd shares

What are today's traded volumes of Granules India Ltd?

Today's traded volume of Granules India Ltd(GRANULES) is 4.64L.

What is today's market capitalisation of Granules India Ltd?

Today's market capitalisation of Granules India Ltd(GRANULES) is ₹11793.68Cr.

What is the 52 Week High and Low Range of Granules India Ltd?

Granules India Ltd (GRANULES)
Price
52 Week High
₹721
52 Week Low
₹389.35

How much percentage Granules India Ltd is down from its 52 Week High?

Granules India Ltd (GRANULES) share price is ₹486.35. It is down -32.55% from its 52 Week High price of ₹721

How much percentage Granules India Ltd is up from its 52 Week low?

Granules India Ltd (GRANULES) share price is ₹486.35. It is up 24.91% from its 52 Week Low price of ₹389.35